A recent episode of the Matt Walker Podcast, titled “Acting Out Dreams,” explored REM Sleep Behavior Disorder (RBD), a condition in which the normal muscle paralysis that protects the body during REM sleep fails.
Walker explained that in healthy REM sleep, the brain remains highly active while the body is effectively immobilized, preventing dream enactment. In RBD, that safeguard breaks down. Individuals may shout, punch, kick, or leap from bed while still asleep, sometimes resulting in significant injury to themselves or their bed partners.
He highlighted an important clinical observation: idiopathic RBD, where symptoms occur without a diagnosed neurological condition, is associated with an increased likelihood of developing neurodegenerative diseases over time, including Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Walker emphasized the importance of awareness, appropriate sleep evaluation, and timely referral when symptoms arise.
The episode also addressed practical strategies to reduce injury risk, including environmental safety measures, and specialist involvement. Walker also pointed to a growing area of research focused on early detection and biomarkers in individuals considered higher risk.
One area of interest involves detecting abnormal forms of alpha-synuclein, a protein linked to several neurodegenerative conditions. Walker discussed techniques such as the Syn-One Test, which uses small biopsies to detect phosphorylated alpha-synuclein deposits in peripheral nerves.
Walker noted that skin biopsy is just one of several tools to support the understanding and implications of a diagnosis of RBD. Researchers are also exploring cerebrospinal fluid assays, advanced imaging, autonomic function testing, olfactory assessments, and detailed cognitive evaluations to better understand risk and disease progression.
Throughout the episode, Walker emphasized that RBD should not be dismissed as merely a sleep disturbance but rather considered within the broader context of brain health, including its potential role in identifying early risk of neurodegenerative disease.
Listen to the full episode
